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Growth hormone initiates signaling by inducing ho-
modimerization of two GH receptors. Here, we have
sought to determine whether constitutively active re-
ceptor can be created in the absence of the extracellular
domain by substituting it with high affinity leucine zip-
pers to create dimers of the growth hormone receptor
(GHR) signaling domain. The entire extracellular do-
main of the GHR was replaced by the hemagglutinin-
tagged zipper sequence of either the c-Fos or c-Jun tran-
scription factor (termed Fos-GHR and Jun-GHR,
respectively). Transient transfection of Fos-GHR or Jun-
GHR resulted in activation of the serine protease inhib-
itor 2.1 promoter in Chinese hamster ovary-K1 cells to a
level equal to that achieved by fully activated wild type
GHR. Furthermore, stable expression of Jun-GHR alone
or Fos-GHR and Jun-GHR together in the interleukin
3-dependent BaF-B03 cell line resulted in cell prolifera-
tion after interleukin 3 withdrawal at a rate equal to
maximally stimulated wild type GHR-expressing cells.
Activation of STAT 5b was also observed in Fos-Jun-
GHR-expressing cells at a level equal to that in chroni-
cally GH-treated GHR-expressing cells. Thus, forced
dimerization of the transmembrane and cytoplasmic do-
mains of the GHR in the absence of the extracellular
domain can lead to the constitutive activation of known
GH signaling end points, supporting the view that prox-
imity of Janus kinase 2 (JAK2) kinases is the essential
element in signaling. Such constitutively active GH re-
ceptors may have particular utility for transgenic live-
stock applications.
Growth hormone (GH)1 is a potent regulator of somatic
growth and a broad spectrum of metabolic processes. Its wide
variety of effects on target cells are mediated by a single mem-
brane-spanning receptor (GHR), which is expressed in over 40
different tissues (reviewed in Ref. 1). The GHR is a class 1
homomeric cytokine receptor belonging to the same group as
erythropoietin receptor, prolactin receptor, thrombopoietin re-
ceptor, and granulocyte colony-stimulating factor receptor (G-
CSFR), all of which homodimerize upon ligand binding to form
a complex consisting of one ligand and two identical receptor
subunits. This contrasts with other class 1 cytokine receptors,
which undergo heterodimeric or multimeric associations in re-
sponse to ligand binding (reviewed in Ref. 2). Early studies
showed that GH binds via a high affinity interaction with one
GH receptor, followed by a lower affinity interaction with the
second identical GHR forming a GH(GHR)2 trimeric complex
(3). Formation of this complex is the first step in signal trans-
duction, which is presumed to bring together and activate two
JAK2 molecules, each of which associates with a highly con-
served membrane proximal proline rich region in the cytoplas-
mic domain referred to as box 1 (4). Activation of JAK2 results
in activation of signaling molecules, such as STATs, MAP ki-
nases, phosphatidylinositol 39-phosphate kinase, and protein
kinase C, and elevates intracellular calcium, leading to the
transcriptional regulation of many genes (4).
The biological role of GHR dimerization was first studied by
Fuh et al. (5) using a cell line that expressed a chimeric receptor
consisting of the binding domain of GHR fused to the extracel-
lular fibronectin and cytoplasmic domains of the G-CSFR.
These workers showed that wild type GH could trigger prolif-
eration in these cells, although a GH analogue with an un-
favourable substitution in the low affinity site 2 domain was
unable to cause proliferation, because it was unable to induce
GHR dimerization. These workers also reported that mono-
clonal antibodies to the GHR were able to elicit a full prolifer-
ative response in these cells, presumably by dimerizing the
chimeric receptor in a fashion analogous to GH. More recently,
we have studied the importance of interreceptor interactions by
creating mutations in the dimerization domain, the only con-
tact domain between the two receptor sub-units (6). We found
that charge reversal mutagenesis severely reduced the ability
of the receptor to signal, presumably by preventing trimeric
complex formation. Thus, there is strong support for the essen-
tial role of dimerization in GHR signal transduction, with
alignment of the two receptors being set by bonding interac-
tions across the dimerization domain.
Given this view, dimerization of receptor subunits by means
of bivalent antibodies should result in signal generation. How-
ever, although monoclonal antibodies to the extracellular do-
main of the GH receptor are able to generate full proliferative
responses in FDCP-1 lines expressing a chimera of the GH
receptor (extracellular) fused to the G-CSFR (4, 7), these same
antibodies are unable to support proliferation of FDCP-1 cells
expressing full-length GH receptor (7). Thus, of 15 anti-GHR
mAbs examined, none could induce proliferation in FDC-P1
cells expressing the full-length GHR, whereas 8 could induce
proliferation in the FDC-P1 cells expressing the G-CSFR chi-
mera used by Fuh et al. (5). Two mAbs could cause the more
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sensitive hGHR-BaF-B03 cells to proliferate, but they did so
very weakly (maximum 23% of GH level). These results raise
the possibility that dimerization of the GHR alone is not suffi-
cient for its activation and raise questions about its mode of
action, including the possible requirement for a specific hor-
mone-induced conformational change for signaling (see discus-
sion in Ref. 7), a view supported by another recent study using
monoclonal antibodies to the GH receptor (8). Very recently a
crystallographic study of the closely homologous erythropoietin
receptor has shown that it can exist as a preformed dimer by
virtue of inter receptor interactions located in the same loops of
the receptor that otherwise bind the hormone (9). Furthermore,
this preformed dimer places the membrane entry points of the
extracellular domain around 73 Å apart, whereas the hormone
bound receptor dimer has entry points around 39 Å apart (9).
Using an elegant fragment complementation assay, Remy et al.
(10) presented evidence that a conformational change results
from hormone binding, which brings the membrane entry
points close together, paralleling the subunit relationships
seen with the crystal structures of the unbound and ligand
occupied receptor dimers. This new paradigm for cytokine re-
ceptor signaling could explain the difficulty in obtaining ago-
nist responses with monoclonal antibodies to the GH receptor,
because only a small subset would be able to trigger the con-
formational changes necessary to bring the membrane proxi-
mal sequences into proximity. Indeed, a similar study per-
formed with the EPO receptor found that only 4 of 96
monoclonal antibodies to the extracellular domain were able to
activate the receptor (11).
Whether the original sequential dimerization model or the
preformed dimer/conformational change model applies to the
GH receptor, it should be possible to create constitutively ac-
tive GH receptors if the receptor subunits are correctly aligned
in appropriate proximity. This study seeks to establish whether
constitutive activation can be achieved simply by dimerizing
the transmembrane and cytoplasmic domains through the use
of leucine zippers (22). A leucine zipper is an a-helix with
leucine resides (generally five) presented at every seventh po-
sition along its length. In solution, two complimentary zippers
will form high affinity dimers aided by strong hydrophobic
forces from juxtaposed leucines. Leucine zippers are found as
part of certain transcription factors, such as c-fos and c-jun that
form the AP-1 transcription complex. Zippers from c-fos and
c-jun can homo- or heterodimerize in solution, although ther-
modynamic analyses have shown that fos-jun heterodimers are
more stable than jun homodimers, which are considerably more
stable than fos homodimers (Tm of 71 °C for heterodimer pep-
tide, 69 °C for Jun homodimer peptide, and 59 °C for Fos ho-
modimer peptide (12)), as a result of electrostatic interactions
between helices that involve residues adjacent to the leucines.
Fusing the transmembrane and cytoplasmic domains of GHR
to these zippers provides a means of achieving GH-independent
dimerization. By expressing these chimeras in cell systems
that are known to respond to GH, we have tested their signal-
ing capabilities, to determine whether it is possible to create a
constitutively active GH receptor.
EXPERIMENTAL PROCEDURES
Expression Plasmid Construction
Polymerase chain reaction was used to amplify the cDNA encoding
the 27 amino acid signal peptide from porcine GHR (pGHR) such that
the product included a 59 HindIII restriction site and a 39 BamHI
restriction site (Fig. 1). This fragment was then cloned into the expres-
sion vector pcDNA3.11 (Invitrogen). Synthetic oligonucleotides encod-
ing the hemagglutinin (HA) tag (YPYDVPDYAS) (12) were annealed
and cloned into the pcDNA 3.11 vector (contains the neomycin resist-
ance gene) downstream of the pGHR signal peptide sequence at BamHI
and EcoRI sites. Synthetic oligonucleotides encoding either the mouse
c-Fos leucine zipper (amino acids 162–200) or the mouse c-Jun leucine
zipper (amino acids 277–315) that contained a 59 EcoRI site and a 39
NotI site were annealed and cloned into the vector downstream of the
HA tag. Polymerase chain reaction was used to amplify the GHR
transmembrane and cytoplasmic domains (amino acids 251–638) such
that the product included a 59 NotI and a 39 XbaI overhang that was
then cloned downstream of the leucine zipper. The entire insert was
sequenced and found to contain no errors. Eleven residues of receptor
sequence were left at the membrane proximal end of the domain be-
tween the zipper sequence and the transmembrane sequence to allow a
degree of flexibility similar to that of wild type GHR. The leader se-
quence was identical to that for full-length GHR, ensuring identical
posttranslational trafficking and surface expression. These constructs
are hereafter termed Fos-GHR and Jun-GHR, respectively.
Finally, as a control for Fos/Jun mediated dimerization, a construct
was created that lacked the zipper coding sequences, so that the first of
the remaining 11 extracellular residues was linked directly to the HA
tag coding sequence. This was undertaken by excising the zipper/pGHR
(251–638) coding sequence with EcoRI/XbaI, and replacing it with the
pGHR (251–638) coding sequence derived by polymerase chain reaction
to contain an EcoRI site at the 59end, so as to be compatible with the
39EcoRI site of the HA tag coding sequence.
Transient Transfection of 293 Cells
Human kidney 293 cells were cultured in DMEM containing 10%
fetal bovine serum. Cells at 50% confluency in a 10-cm dish (1 day after
passage) were transiently transfected by a calcium phosphate proce-
dure: DNA-precipitate was made by mixing 500 ml of 0.25 M CaCl2 with
20 mg of eukaryotic expression vector followed by dropwise addition to
500 ml of 23 HBS (50 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesul-
fonic acid, 280 mM NaCl, 1.5 mM Na2HPO4, pH 6.96). The precipitate
was left for 15 min and subsequently added dropwise to cells after
removal of medium, followed by 15 ml of medium then incubation in a
humidified atmosphere containing 5% carbon dioxide. The next day, the
medium was changed, and cells were removed to a humidified atmo-
sphere containing 5% carbon dioxide for a further 24 h.
CHO-K1 Cell Culture, Transfection, and Spi 2.1-Chloramphenicol
Acetyltransferase (CAT) Assay
This was performed as described in Hansen et al. (13). Briefly, cells
were co-transfected with 3 mg of plasmid containing the b-galactosidase
gene, 1.5 mg of Spi 2.1-CAT reporter construct, and varying amounts of
chimeric receptor plasmid using the calcium phosphate method. After
48 h, cells were lysed, and extracts were normalized for b-galactosidase
activity before the CAT assay was performed. As a control, 1.5 mg of
pGH receptor expression construct was transfected in place of the
chimera constructs, and cells were stimulated with 20 nM hGH.
BaF-B03 Cell Culture and Transfection
BaF-B03 cells (gift from Dr Tom Gonda, Hanson Institute, Adelaide,
Australia) were cultured in RPMI 1640 medium supplemented with
10% serum supreme (a fetal bovine substitute supplied by BioWhit-
taker Corp.) and 40 ng/ml murine IL-3 (gift from Dr Andrew Hapel,
John Curtin School of Medical Research, Canberra, Australia). 5 3 106
mid-log phase cells were electroporated in 250 ml of phosphate-buffered
saline (PBS) in the presence of 20 mg of expression plasmid at 270 V,
960 mF in a 0.4-cm cuvette (Bio-Rad). Cells were cultured for 2 days in
the above mentioned media before being washed twice with PBS and
placed in selection media. Cells transfected with chimeric plasmid were
selected in 10% serum supreme alone, whereas those transfected with
the pGHR plasmid were selected with 4.5 nM hGH. After several days,
cells were plated at a limiting dilution, and single cells were isolated
and maintained in their respective selection media. In the case of the
Fos-GHR expression plasmid, cells were co-transfected with a geneticin
resistance plasmid, followed by selection with 1.5 mg/ml G418 for at
least 4 days. pGHR-expressing cells were characterized for receptor
expression by 125I-hGH binding assay and Scatchard analysis as de-
scribed in Ref. 14. This involved growing the cells in IL-3 (40 ng/ml) and
10% serum supreme, harvesting, and then incubating them overnight
at 4 °C in isotonic glucose binding buffer with labeled hGH in the
presence of increasing concentrations of hGH (14).
Cell Proliferation Assay
Cells were suspended in RPMI medium supplemented with 0.5%
serum supreme and plated in rows at a variety of cell densities in a 96
well plate. Quadruplicate wells containing pGHR-expressing clones
were incubated with either 4.5 nM GH (maximal), 4.5 nM IL-3 (maxi-
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mal), or no cytokine. Clones expressing the chimera were incubated as
above except that no GH incubation was included. After 18–24 h of
incubation at 37 °C in 5% CO2 in a humidified box with no plate lids,
either 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (fi-
nal concentration, 1 mg/ml) or [3H]thymidine (0.5 mCi/well) was added,
and the incubation was continued for a further 3 h. 3-(4,5-Dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were completed
as described in Ref. 14. [3H]Thymidine assays were completed by har-
vesting cells onto glass fiber filters and counting in a 96-well plate
scintillation counter (Wallac Oy, Turku, Finland).
Immunoprecipitation and Immunoblotting
BaF-B03 Cells—1 3 108 cells were harvested by centrifugation and
washed once with PBS before storage at 270 °C. Lysis was performed
on ice in 2 ml of lysis buffer containing “Complete” inhibitor (Roche
Molecular Biochemicals) (140 mM NaCl, 50 mM Tris-HCl, pH 7.2, 0.4%
Triton X-100, 1 mM EGTA, 1 mM Na3VO4, 10 mM NaF), and the lysate
was cleared by centrifugation at 15,000 rpm in a refrigerated benchtop
centrifuge for 10 min. To the supernatant from the chimera-expressing
clones, 80 mg of a polyclonal antiserum raised against the cytoplasmic
domain of the rabbit GH receptor (15) was added; the mixture was then
incubated at 4 °C for 1 h, followed by the addition of 20 ml of protein
A-Sepharose slurry and 20 ml of protein G-Sepharose slurry (1:1 mix-
ture; Amersham Pharmacia Biotech) and a further 1 h incubation at
4 °C. In experiments comparing the levels of expression of wild type
pGHR and Jun GHR clones (see Fig. 6), 30 mg of a rabbit antiserum
raised against a GST fusion of the rat GHR cytoplasmic domain was
used for immunoprecipitation of both. However, for most studies on
pGHR-expressing clones, 10 mg of mAb 263 (directed to the extracellu-
lar domain of GHR, from Agen Biomedicals, Acacia Ridge, Australia)
was added, and cleared lysates were incubated at 4 °C for 1 h, followed
by addition of Tris-HCl, pH 8.5, to a final concentration of 50 mM, and
then protein A/G-Sepharose was added as described above. These beads
were washed three times in lysis buffer, resuspended in 20 ml of 33
concentrated Laemelli sample buffer containing 50 mM dithiothreitol,
and boiled for 4 min before centrifugation again at 5000 rpm and
loading of the supernatant. Samples were electrophoresed under stand-
ard SDS-PAGE running conditions on 7.5 or 9% acrylamide gels (16).
Proteins were blotted onto 0.2 mm nitrocellulose using a semi-dry elec-
troblotter using prestained markers to judge transfer efficiency (Kalai-
descope, Bio-Rad) and blocked for 1 h in 5% nonfat milk. Blots contain-
ing the chimeric protein were probed with a mAb raised against the HA
tag (clone 3F10, Roche Molecular Biochemicals) at a final concentration
of 0.1 mg/ml and detected with an anti-rat IgG horseradish peroxidase-
linked secondary antibody (Amersham Pharmacia Biotech). Blots con-
taining pGHR and Jun GHR (in which levels of expression were com-
pared) were probed with the anti-rabbit GHR cytoplasmic domain
antibody mentioned above at 10 mg/ml and detected with an anti-rabbit
IgG horseradish peroxidase-linked secondary antibody (Amersham
Pharmacia Biotech). All blots were visualized with ECL reagent (Am-
ersham Pharmacia Biotech) and various exposures taken on x-ray film,
which in some cases were subjected to densitometry on a Bio-Rad
GS-700 densitometer.
HEK 293 Cells—The procedure for immunoblotting was essentially
the same as for BaF-B03 cells except that 2% Nonidet P-40 was used
instead of Triton X-100 and the lysis buffer contained 10 mg/ml aproti-
nin and 10 mg/ml leupeptin instead of complete inhibitor. Also, the
anti-rat GHR cytoplasmic domain antiserum (see above) was incubated
overnight in the presence of protein A-Sepharose. Finally, the anti-HA
antibody used for probing was clone 12CA5, not 3F10 (Roche Molecular
Biochemicals).
Fluorescent Activated Cell Sorting
1 3 106 cells were washed twice in PBS, resuspended in cold PBS
containing 1% bovine serum albumin, and placed on ice to prevent
receptor internalization. Wild type GHR-expressing cells were either
sorted directly or subject to down-regulation by treating the cells with
4.5 nM GH for 16 h prior to fluorescence-activated cell sorting. For wild
type GHR-expressing cells, mAb 263 was added to a final concentration
of 17 mg/ml in a volume of 500 ml and left on ice for 1 h. For chimera-
expressing cells, anti-HA mAb (clone 12CA5) was added to a final
concentration of 4 or 17 mg/ml. After two washes with cold PBS, a
secondary anti-mouse Fc portion antibody with a fluorescein isothiocya-
nate label was added to a concentration of 30 mg/ml and incubated for
1 h. Cells were washed twice and then sorted on a FACScalibur (Becton
Dickinson).
Electrophoretic Mobility Shift Assay
1 3 107 BaF-B03 cells were washed with PBS, resuspended in RPMI
medium supplemented with 0.5% serum supreme, and then incubated
for 8 h at 37 °C. Cells were harvested by centrifugation, and nuclear
extracts were prepared as described in Ref. 17, except for pGHR-ex-
pressing cells, which were treated with 4.5 nM hGH for 20 min or 16 h
prior to harvesting. Electrophoretic mobility shift assay was performed
as described in Ref. 7 except that aprotinin, leupeptin, and Pefabloc
were replaced with Complete inhibitor (Roche Molecular Biochemicals),
and the oligonucleotide probe contained the consensus binding site for
STAT 5 (AGATTTCTAGGAATTCAATCC, Santa Cruz Biotechnology,
sc-2565). Supershift experiments were performed by adding 1 mg of
either STAT 5a antibody (Santa Cruz Biotechnology, sc-1081) or STAT
5b antibody (Santa Cruz Biotechnology, sc-835) to the reaction after the
addition of probe and incubating the mixture for 1 h on ice.
RESULTS
Construction of Expression Plasmids—Two chimeric cDNA
molecules were made such that when co-expressed, two iden-
tical cytoplasmic domains of the GHR are brought into close
proximity (see Fig. 1). Each chimera contains the leucine zipper
sequence from either c-Fos or c-Jun in place of almost the
entire porcine GHR extracellular domain sequence as well as
the HA tag at the amino terminus of the mature protein. A
control construct lacking the zipper sequence was also made.
Dimerization of Fos-GHR and Jun-GHR—To test the ability
of Fos-GHR and Jun-GHR to dimerize, HEK 293 cells (known
for high level expression) were transiently transfected with
each expression construct and the chimeric protein was ana-
lyzed by Western blot. Fig. 2 shows that both Fos-GHR and
Jun-GHR can homodimerize and that this dimer is stable
enough to withstand denaturing conditions in the presence of
reductant.
Activation of the Spi 2.1 Promoter by Fos-GHR and Jun-GHR
in CHO-K1 Cells—As an initial test for activity of the chimeras,
the constructs were transiently expressed in CHO-K1 cells
along with a reporter construct consisting of the Spi 2.1 pro-
moter linked to the CAT reporter gene (13). Fig. 3 shows that
increasing amounts of transfected chimeric plasmids, together
or separately, result in increasing levels of reporter gene activ-
ity, to a point that is equivalent to the maximum amount
achieved by full-length GHR triggered with GH (20 nM hGH). It
should be noted that the Fos-GHR chimera was just as capable
of activating the reporter gene as the Jun-GHR chimera, indi-
cating that productive Fos-GHR homodimers are forming (see
below). Specificity in signaling is apparent, because no signal-
ing was seen by the chimera when all of its cytoplasmic tyro-
sine residues were mutated to phenylalanine, which accords
with the requirement for STAT 5 docking through its SH2
domain for activation (4, 13). In order to demonstrate the
functional role of the Fos/Jun zippers, a construct without the
zipper coding sequence, but otherwise identical, was included
in the analysis. This construct was able to produce some con-
stitutive activation of the Spi 2.1 promoter, although equiva-
lent activation to that produced by Fos or Jun-GHR required
around 75-fold higher concentration of this expression con-
struct (Fig. 3).
Creation of Stable BaF-B03 Cells Lines—The IL-3-dependent
pro B cell line BaF-B03 has been previously shown to respond
to very low levels of GH when stably transfected with human
and rabbit GHR (7, 18). The sensitivity of BaF-B03 cells to GH
makes them an ideal system to test the signaling ability of the
Fos-GHR and Jun-GHR chimeras in a physiologically relevant
way. Transfection of full-length porcine GHR and selection
with GH yielded colonies that were cloned by limiting dilution
and characterized. A clone (named pGHR-BaF) was chosen
that expressed 3457 6 646 surface receptors per cell with an
affinity of 3.6 6 0.3 3 109 M21, as determined in serum starved
cells (14). When BaF-B03 cells were transfected with Jun-GHR
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plasmid alone or co-transfected with Fos-GHR plasmid, cyto-
kine-independent cell proliferation was observed, and these
cells were cloned by limiting dilution (named Jun-BaF and
Fos/Jun-BaF, respectively). However, despite several attempts,
no colonies were evident in populations transfected with Fos-
GHR alone. Transfection efficacy was confirmed in these pop-
ulations by performing a parallel selection with G418 that
yielded numerous colonies with IL-3 support.
Expression of Fos-GHR and Jun-GHR Chimeras in BaF-B03
Cells—Immunoprecipitation and blotting demonstrated correct
expression of the chimeric and full-length receptors (Fig. 4). In
the case of Fos-GHR, G418-resistant populations were used to
confirm expression of the chimera because no constitutively
proliferating colonies were obtained. Despite the fact that Jun-
GHR homodimers and Fos-GHR/Jun-GHR heterodimers can
cause proliferation, Western blotting was unable to show the
formation of the dimeric complex in BaF-B03 cells.
In order to estimate the relative expression levels of wild
type and Jun-GHR proteins, a number of lines expressing Jun-
GHR were compared with the line expressing 3457 6 646 wild
type pGHR surface receptors per cell by immunoblot. In this
comparison, solubilized cell extracts of 1 3 108 cells were im-
munoprecipitated with one antibody to the cytoplasmic domain
of the receptor, and probed with another (Fig. 4A). Densitomet-
ric analysis provided estimates of 81, 107, 225, and 249% of
wild type pGHR expression for four Jun GHR clones, and the
thymidine incorporation rates of these clones were 67 6 1, 76 6
0.8, 106 6 2, and 141 6 1%, respectively, those of wild type
pGHR (see below). It should be noted that the level of expres-
sion of zip-GHR constructs (as determined by immunoblot as
above) was vastly greater in HEK 293 cells and CHO-K1 cells
transiently transfected with zip-GHR expression constructs
(results not shown).
Surface Expression of Fos-GHR and Jun-GHR in BaF-B03
Cells—Fluorescence activated cell sorting using the anti-HA
antibody was performed on Fos/Jun-BaF clones to measure
surface expression. Even at high antibody concentrations, very
FIG. 1. Schematic description of leucine zipper chimeras. A, Fos-GHR chimeric cDNA. B, Jun-GHR chimeric cDNA. C, Fos-GHR or
Jun-GHR chimeric cDNAs with all intracellular tyrosines mutated to phenylalanine. D, GHR chimeric cDNAs with the zipper sequence removed.
Numbers in parentheses refer to the amino acid sequence from which the respective cDNA segments were taken. Junctions are annotated with the
restriction sites used in construction.
FIG. 2. Immunoblot of Fos-GHR and Jun-GHR expressed in
HEK 293 cells. Immunoprecipitation and immunoblot were performed
as described under “Experimental Procedures.” Cleared cell lysates
were either immunoprecipitated with antiserum to rat GHR cytoplas-
mic domain or with preimmune serum, then probed with HA tag anti-
body. Lane 1, untransfected cells; lane 2, Fos-GHR (preimmune serum);
lane 3, 0.5 mg of Fos-GHR; lane 4, 1.0 mg of Fos-GHR; lane 5, Jun-GHR
(preimmune serum); lane 6, 0.5 mg of Jun-GHR; lane 7, 1.0 mg of
Jun-GHR. Molecular weights are indicated on the left. The image
shown is representative of three independent experiments.
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low cell fluorescence was detected in the clones expressing the
chimeras (Fig. 5A). This level of fluorescence is very similar to
that found when pGHR-BaF cells are treated with 20 nM hGH
for 16 h, a stimulus that is known to down-regulate the recep-
tor by a factor of 10 (Fig. 5B) (14). It appears that because the
chimeric receptor is constitutively active, it is constantly in a
down-regulated state.
Proliferation Rates of Clones Expressing Chimeric Recep-
tors—3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide and [3H]thymidine incorporation assays were used to
demonstrate that proliferation rates of Jun-BaF and Fos/Jun-
BaF clones are almost identical to that achieved by pGHR-BaF
when stimulated with a maximal dose of GH (20 nM, Fig. 6).
Rates have been normalized to each clones ability to proliferate
in response to a maximal dose of IL-3, which corrects for in-
trinsic differences in the ability of clones to proliferate. In the
case of the pGH receptor-expressing clone, this was 54 6 2.6%
(n 5 10) of the maximal IL-3 response.
STAT 5 Induction by Clones Expressing Chimeric Recep-
tors—STAT 5 is a latent transcription factor that is phospho-
rylated by JAK2 in response to receptor activation and is
known to bind a specific cis element in response to GH. Fig. 7A
shows that the amount of STAT 5 that is able to bind DNA in
the Fos/Jun-BaF clones is equivalent to that in pGHR-BaF cells
that have been treated for 16 h with 20 nM GH. As determined
by band densitometry, this level of STAT 5 activation is ap-
proximately 6-fold less than that present after 20 min of GH
treatment of GH starved pGHR-BaF cells. This time has been
shown to result in maximal activation of STAT 5 binding (re-
sults not shown). The induced STAT 5 is shown to be STAT 5b
FIG. 3. Spi2.1-CAT reporter gene activity of Fos-GHR (open columns), Jun-GHR (striped columns), Fos-GHR plus Jun-GHR (black
columns), and minus zipper (cross-hatched columns) chimeras expressed in CHO-K1 cells. Increasing amounts of expression plasmid
were transiently transfected and cells assayed as described under “Experimental Procedures.” Micrograms shown for Fos-GHR plus Jun-GHR
co-transfections are totals comprising equal amounts of each plasmid. Activity is expressed as a percentage of maximally stimulated wild type
pGHR-expressing cells transfected with 1.5 mg of plasmid and stimulated with 20 nM hGH. The far right columns (No Tyr) show the level of activity
of chimeras that have all intracellular tyrosines mutated to phenylalanine (1.5 mg transfected). The level of activity for the construct lacking a
zipper domain is shown for the 0.02, 0.1, and 1.5 mg amounts. Results shown are the mean 6 S.E. of three independent experiments.
FIG. 4. Immunoblot of Fos-GHR and Jun-GHR expressed in BaF-B03 cells. Immunoprecipitation and immunoblot were performed as
described under “Experimental Procedures,” using anti-rabbit GHR cytoplasmic domain for immunoprecipitation and HA tag antibody as probe,
except for A, in which case the rat GHR cytoplasmic antiserum was used for immunoprecipitation and rabbit GHR cytoplasmic antiserum was used
as probe, in order to facilitate comparison of expression level for Jun-GHR and wild type pGHR. A, lanes 1–4, different clones of Jun-GHR (lanes
1 and 2, high level expression; lanes 3 and 4, low level expression); lane 5, wild type pGHR. B, lane 1, untransfected cells; lanes 2–4, constitutively
proliferating clones 1–3 expressing both Fos-GHR and Jun-GHR together. C, lane 1, untransfected cells; lanes 2 and 3, two independently
transfected G418 resistant populations expressing Fos-GHR. D, lane 1, untransfected cells; lanes 2–4, constitutively proliferating clones 1–3
expressing Jun-GHR. Molecular weights are indicated on the left (31023). Images shown are representative of at least two independent
experiments.
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because it is supershifted by the addition of anti-STAT 5b
antibody to the reaction mixture before gel loading (Fig. 7B).
DISCUSSION
A central problem in class 1 cytokine receptor signaling is
defining the means used by the hormone to induce proximity of
the Janus kinase molecules bound to the membrane proximal
box 1 sequence in the cytoplasmic domain. Proximity of the
JAKs induces transphosphorylation and activation, initiating a
variety of signaling pathways. The work presented here shows
that appropriate dimerization of cytoplasmic domains is all
that is required to generate a fully active receptor.
Because we were unable to fully activate the receptor
through the use of bivalent antibodies, we have used leucine
zipper/GHR chimeras that dimerize in the absence of ligand
without the extracellular hormone binding domain. We chose
this approach because such zippers are likely to form closely
apposed dimers, thus avoiding the possibility that steric con-
straints related to mAb size are preventing the close associa-
tion of the GHR cytoplasmic domains. Crystal structures of
Fos-Jun zippers (19) show that the a-helices are approximately
9 Å apart at their C termini, suggesting that the Fos-GHR and
Jun-GHR chimeras would be similarly spaced in the mem-
brane. This distance is closer than the 29 Å distance between
the most membrane proximal residue of the receptor resolved
in the 2:1 complex (i.e. between the a-carbons of proline 234)
based on both the DeVos et al. (20) structure and the Sund-
strom et al. (21) structure. However, the presence of an 11-
residue residual receptor sequence just above the membrane,
linking the remainder of the receptor to the leucine zippers,
may introduce an element of flexibility in the alignment of box
1. Our modeling of this linker region and the transmembrane
domain indicates the existence of a b-turn that may help to
position the a-helical transmembrane domains more closely
together.2 Whatever the role of this 11-residue linker, attach-
ment of the zippers to it has allowed us to mimic the placement
of the engaged dimerization domain as well as avoiding any
problems that may arise from situating the zipper too close to
the cell surface (e.g. phospholipid headgroup interference).
The finding that a dimerized GHR lacking its extracellular
domain can signal effectively does not preclude the possibility
that the extracellular domain of the full-length GHR undergoes
a local conformational change in response to GH binding that is
necessary for proper alignment of the intracellular signaling
domains. Such a conformational change could be analagous to
that proposed for the predimerized erythropoietin receptor,
discussed in the Introduction (9, 10), which must result in
correct apposition (alignment) of the bound JAK2 molecules for
effective signaling. This is demonstrated by the crystal struc-
tures of small molecule agonists and antagonists of the EPO
receptor, which show different angular displacements of the
receptor subunits (22, 23). There is evidence that binding of
JAK2 to the GH receptor increases as a result of hormone
binding (24), which could be the result of a conformational
change in the box 1 region or of additional interactions between
bound JAK2 molecules brought about by their apposition.
JAK2 can be activated through dimerization, as demonstrated
by use of a GH receptor-JAK2 chimera with the cytoplasmic
domain substituted by JAK2 (25). This enabled activation of
JAK2 on addition of hormone (presumably by transphosphoryl-
ation), suggesting that proximity rather than precise align-
ment is required.
Co-transfection of CHO-K1 cells with the Spi 2.1-CAT re-
porter gene and increasing amounts of Fos-GHR or Jun-GHR
cDNAs resulted in a level of promoter activity equivalent to
that achieved by a maximally activated wild type GHR (see Fig.
3). This implies that the chimeras are able to dimerize and
activate JAK2 normally and also to activate STAT 5 because
this signaling molecule has been shown to bind a specific ele-
ment in the Spi 2.1 promoter in response to GH (26). Mutation
of all the intracellular tyrosines to phenylalanine prevented
both chimeras from signaling, demonstrating that the signal-
ing seen with the Fos-GHR and Jun GHR is originating from
the GHR cytoplasmic domain and is not an artifact of over
expression of leucine zippers, for example by sequestering en-
dogenous c-Fos or c-Jun. It has been reported that, in solution,
Fos zippers form only weak homodimers, although they form
strong heterodimers with Jun zippers, whereas Jun zippers can
also form reasonably strong homodimers (12). It was therefore
surprising to find that Fos-GHR was able to activate the Spi
2 K. Neilsen, R. Brown, and M. J. Waters, unpublished data.
FIG. 5. Representative fluorescence-activated cell sorting pro-
file of BaF-B03 clones expressing Fos-GHR and Jun-GHR to-
gether. Immunostaining and cell sorting were performed as described
under “Experimental Procedures.” A, dotted line, untransfected cells;
boldface line, BaF-B03 cells expressing wild type GHR in the absence of
GH; thin line, BaF-B03 cells expressing wild type GHR after 16 h of GH
treatment using mAb 263 (17 mg/ml) as probe. B, dotted line, untrans-
fected cells; boldface line, constitutively proliferating BaF-B03 cells
expressing Fos-GHR and Jun-GHR together, using 17 mg/ml HA anti-
body as probe. Data shown are representative of at least three inde-
pendent experiments performed on three separately isolated clones.
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2.1-CAT reporter equally as well as the Jun-GHR chimera,
indicating equivalent Fos-GHR homodimer formation. In order
to explain this result, it is important to remember that two-
dimensional interactions in the plane of the cell membrane are
considerably more favorable than those in solution (27). Al-
though the tendency for Fos-GHR to homodimerize would be
weak in solution (Kd 6 mM (12)), such dimers are likely to be
stabilized when aligned in the cell membrane. In support of
this, Patel et al. (28) showed that a chimera of the Fos zipper
sequence fused to the granulocyte-macrophage colony-stimu-
lating factor receptor was able to form a disulfide-bridged
dimer if a free cysteine is added near its amino terminus. This
suggests that the Fos zipper sequence is capable of forming
homodimers to some degree, and because the level of expres-
sion in CHO-K1 cells is high (relative to that in BaF cells), it is
likely that the excess receptor forces the dimerization equilib-
rium toward homodimer formation. Furthermore, in a cell that
expresses a greater number of receptors than effector mole-
cules such as JAK2 (i.e. “spare receptors”), only a relatively
small proportion of those receptors is required to yield a max-
imal response from the cell (29). Therefore, in the case of
transient transfection of CHO-K1 cells, it appears that the
weak tendency for Fos-GHR to homodimerize is sufficient to
enable coupling of dimers to all the available effector mole-
cules, resulting in a maximal response. Indeed, as we show in
Fig. 3, even in the absence of a zipper sequence, there is some
constitutive activity, although it requires around 75-fold higher
concentration of expression plasmid. This may be a result of the
high level of expression in CHO cells, or there may be weak
interreceptor interactions between transmembrane and/or cy-
toplasmic domains.
In contrast to the transiently transfected CHO-K1 cells, BaF-
B03 cells that were stably transfected with Fos-GHR were
unable to proliferate upon the withdrawal of IL-3 despite sev-
eral transfections. Expression was confirmed by Western blot-
ting of cells that were selected in parallel with G418 (see Fig.
4C). Based on immunoblot, the level of stable expression of the
chimeras in BaF-B03 cells is far lower than that seen in
CHO-K1 cells, so that the dimerization equilibrium will favor
unproductive monomers. Alternatively, it is possible that the
weak, short lived homodimerization of Fos-GHR is insufficient
to recruit the signaling molecules required for proliferation in a
BaF-B03 cell, whereas it is sufficient to recruit JAK2 and STAT
5 in a CHO-K1 cell. When the Fos-GHR and Jun-GHR con-
structs were co-transfected, IL-3 withdrawal yielded constitu-
tively proliferating colonies. Clones from these colonies prolif-
erated at levels similar to pGHR-BaF cells that were
maximally stimulated with GH (see Fig. 6). Similar results
were obtained when Jun-GHR was transfected alone, confirm-
ing previous work showing that Fos and Jun zippers form
strong heterodimers and Jun can form strong homodimers.
Comparative immunoblot analysis (Fig. 4A) indicates that the
Jun-GHR chimeras and the wild type pGHR are expressed at
similar level, which implies that the chimera is functioning
with similar efficiency to the wild type receptor.
Based on the fact that the Spi 2.1 promoter was activated by
the chimeras in CHO-K1 cells, it was thought that STAT 5
would be up-regulated in Fos/Jun-BaF cells. EMSA showed
FIG. 6. Constitutive proliferation of BaF-B03 cells stably expressing Jun-GHR (open columns) and Fos-GHR plus Jun-GHR
together (black columns). Proliferation levels (as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye incorporation)
of three independently isolated clones were measured as described under “Experimental Procedures.” Results are shown as a percentage of a wild
type pGHR-expressing clone maximally stimulated with 4.5 nM GH after being normalized to the maximal proliferation rate of each clone in
response to IL-3. Untreated wild type pGHR-expressing cells were used to measure background for constitutively proliferating clones. Results
shown are the mean 6 S.E. of at least three independent experiments. All results were confirmed with [3H]thymidine incorporation assay.
FIG. 7. Electromobility shift and supershift assay of BaF-B03
clones expressing Fos-GHR and Jun-GHR together. Nuclear ex-
traction, oligonucleotide binding and supershifts were performed as
described under “Experimental Procedures,” using a STAT 5 probe. A
(EMSA), lanes 1–3, cells expressing wild type pGHR with either none,
20 min, or 16 h of GH treatment respectively; lanes 4 and 5, two clones
of constitutively proliferating cells expressing Fos-GHR and Jun-GHR
together (no treatment). Relative intensities of marked band are shown
at bottom (arbitrary units). B (supershift), lanes 1–3, cells expressing
wild type pGHR after 20 min 20 nM hGH treatment with either none,
Stat 5a, or Stat 5b antibodies added before gel loading. Extracts were
normalized to Oct-1 binding before loading. Arrow indicates GH-in-
duced band. Note that the loss of band intensity with the STAT 5a
antibody is an artifact of salt concentration and does not indicate a
bandshift.
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that STAT 5 (b isoform, see Fig. 7B) is indeed activated and
binds its consensus sequence in these cells to a degree that is
similar to chronically GH-treated pGHR-BaF cells (Fig. 7A).
This level of induction is 6-fold lower than that achieved after
20 min of maximal GH treatment, presumably due to a combi-
nation of receptor down-regulation and induction of negative
regulatory proteins such as SOCS-3 (suppressor of cytokine
signaling 3) (30). This result is consistent with the notion that
the Fos-GHR/Jun-GHR heterodimer is constitutively active
and is down-regulated in a manner similar to wild type GHR in
the presence of 20 nM GH. This view is supported by the
fluorescence-activated cell sorting data of Fig. 5.
In conclusion, we have been able to generate constitutively
active GH receptors by, in effect, substituting the dimerization
domain with a leucine zipper. In order to rationalize this result
with our previous study using mAbs to the receptor (7), which
suggested that a hormone-induced conformational change may
be necessary for signaling, and the results of Wilson’s group (9,
10), we propose that GH (or the appropriate mAb) induces a
conformational change in the extracellular domain that is nec-
essary for optimum alignment and bonding of the dimerization
domain residues. This stabilizes the receptor dimer in a con-
formation that holds the box 1 sequences in proximity, and it
facilitates signaling. The same result can be achieved with the
leucine zipper chimeras, which mimic the placement of the
engaged dimerization domains. This model is concordant with
the differences observed in disposition of dimerization domain
residues between the 1:1 and 2:1 complexes (31) and empha-
sizes the role of the dimerization domain in correct alignment
of the GH receptor subunits, an element that is unimportant in
the EPO receptor, which lacks such a defined domain.
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